Choosing first-line therapy for chronic lymphocytic leukemia

Expert Review of Anticancer Therapy

Volumn 11, Issue 9, 2011, Pages 1379-1390

  Jaglowski, Samantha ^a   Jones, Jeffrey A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

alemtuzumab; bendamustine; chemoimmunotherapy; chlorambucil; chronic lymphocytic leukemia; cyclophosphamide; fludarabine; pentostatin; risk stratification; rituximab

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; METHYLPREDNISOLONE; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EPSTEIN BARR VIRUS INFECTION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; INFECTION; LYMPHOCYTOMA; LYMPHOMA; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS;

EID: 80053032460     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.132     Document Type: Review

References (92)

1. O'Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85(2), 307-318 (1995).
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 333(16), 1052-1057 (1995).
3. Montserrat E, Gomis F, Vallespi T et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 78(6), 1545-1551 (1991).
4. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 10(1), 37-50 (2010).
5. Rawstron AC, Bennett FL, O'Connor SJ et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med. 359(6), 575-583 (2008).
6. Rai KR, Montserrat E. Prognostic factors in chronic lymphocytic-leukemia. Semin. Hematol. 24(4), 252-256 (1987).
7. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1), 198-206 (1981). (Pubitemid 11064396)
8. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000). (Pubitemid 32064784)
9. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program. 481-488 (2010).
10. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6), 1848-1854 (1999). (Pubitemid 29430400)
11. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J. Clin. Oncol. 24(28), 4634-4641 (2006). (Pubitemid 46630962)
12. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6), 1840-1847 (1999). (Pubitemid 29430399)
13. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348(18), 1764-1775 (2003). (Pubitemid 36514707)
14. Wierda WG, O'Brien S, Wang X et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J. Clin. Oncol. 27(10), 1637-1643 (2009).
15. Hallek M, Langenmayer I, Nerl C et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93(5), 1732-1737 (1999). (Pubitemid 29102502)
16. Reinisch W, Willheim M, Hilgarth M et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 12(10), 2146-2152 (1994). (Pubitemid 24356033)
17. Sarfati M, Chevret S, Chastang C et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 88(11), 4259-4264 (1996). (Pubitemid 26399173)
18. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008).
19. Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on chronic lymphocytic leukemia. N. Engl. J. Med. 338(21), 1506-1514 (1998). (Pubitemid 28226278)
20. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst. 91(10), 861-868 (1999).
21. Ferrajoli A, Keating MJ, O'Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer 117(14), 3182-3186 (2011).
22. Zent CS, Call TG, Shanafelt TD et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 113(8), 2110-2118 (2008).
23. Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50(6), 1049-1059 (1977). (Pubitemid 8245208)
24. Eichhorst BF, Busch R, Stilgenbauer S et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114(16), 3382-3391 (2009).
25. Kimby E, Bjorkholm M, Gahrton G et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann. Oncol. 5(Suppl. 2), 67-71 (1994). (Pubitemid 24061323)
26. Raphael B, Andersen JW, Silber R et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J. Clin. Oncol. 9(5), 770-776 (1991).
27. Bergmann MA, Goebeler ME, Herold M et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase I/ II study of the German CLL Study Group. Haematologica 90(10), 1357-1364 (2005). (Pubitemid 41503651)
28. Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(26), 4378-4384 (2009).
29. Knauf WU, Lissitchkov T, Aldaoud A et al. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 116(21), 2449 (2010).
30. Keating MJ, Kantarjian H, O'Brien S et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 9(1), 44-49 (1991).
31. Keating MJ, O'Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4), 1165-1171 (1998). (Pubitemid 28369029)
32. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750-1757 (2000).
33. Flinn IW, Byrd JC, Morrison C et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96(1), 71-75 (2000). (Pubitemid 30456452)
34. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3), 885-891 (2006). (Pubitemid 43156283)
35. Stilgenbauer S, Zenz T, Winkler D et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial. ASH Annual Meeting Abstracts 112(11), 781 (2008).
36. Oscier D, Wade R, Davis Z et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95(10), 1705-1712 (2010).
37. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a Phase II trial of Cancer and Leukemia Group B. J. Clin. Oncol. 7(4), 433-438 (1989). (Pubitemid 19098136)
38. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116(19), 3705-3714 (2010).
39. Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin's lymphoma. Ann. Oncol. 9(9), 995-1001 (1998). (Pubitemid 28496709)
40. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19(8), 2153-2164 (2001). (Pubitemid 32366969)
41. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19(8), 2165-2170 (2001). (Pubitemid 32366970)
42. Hainsworth JD, Litchy S, Barton JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21, 1746-1751 (2003). (Pubitemid 46638587)
43. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol. J. 2(5), 300-306 (2001). (Pubitemid 32976373)
44. Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 114(14), 3052-3055 (2009).
45. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol. 51(5), 364-369 (1998). (Pubitemid 28289122)
46. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10), 3554-3561 (2002). (Pubitemid 34534522)
47. O'Brien S, Ravandi-Kashani F, Wierda WG et al. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. ASH Annual Meeting Abstracts 106(11), 2960 (2005).
48. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 93(1), 151-153 (1996). (Pubitemid 26132394)
49. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).Blood 100(3), 768-773 (2002). (Pubitemid 34832599)
50. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25(35), 5616-5623 (2007).
51. Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100(9), 3115-3120 (2002). (Pubitemid 35217057)
52. Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).Blood 101(1), 6-14 (2003). (Pubitemid 36025880)
53. Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105(1), 49-53 (2005). (Pubitemid 40053062)
54. Woyach JA, Ruppert AS, Heerema NA et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J. Clin. Oncol. 29(10), 1349-1355 (2011).
55. Del Poeta G, Del Principe MI, Consalvo MA et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 104(12), 2743-2752 (2005). (Pubitemid 41798284)
56. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4), 975-980 (2008).
57. Tsimberidou AM, Tam C, Abruzzo LV et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2), 373-380 (2009).
58. Lin KI, Tam CS, Keating MJ et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113(14), 3168-3171 (2009).
59. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
60. O'Brien S, Wierda WG, Faderl S et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL).ASH Annual Meeting Abstracts 106(11), 2117 (2005).
61. Foon KA, Boyiadzis M, Land SR et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(4), 498-503 (2009).
62. Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 24(10), 1575-1581 (2006). (Pubitemid 46638781)
63. Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109(2), 405-411 (2007). (Pubitemid 46105933)
64. Kay NE, Wu W, Kabat B et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 116(9), 2180-2187 (2010).
65. Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter Phase II trial of the German CLL Study Group (GCLLSG).ASH Annual Meeting Abstracts 114(22), 205 (2009).
66. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26(25), 3644-3653 (2007). (Pubitemid 46842714)
67. Badoux XC, Keating M, O'Brien S et al. Chemoimmunotherapy with cyclophosphomide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL).ASH Annual Meeting Abstracts 114(22), 3431 (2009).
68. Parikh SA, Keating M, O'Brien S et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 114(22), 208 (2009).
69. Remi L, Lepretre S, Christine A et al. CLL2007FMP, a Phase III randomized multicentric trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the 'Groupe Ouest-Est D'etudes Des Leucemies Aigues Et Autres Maladies Du Sang' (GOELAMS): immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) (FCR) yields a significantly better response than fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color flow cytometry MRD. ASH Annual Meeting Abstracts 116(21), 698 (2010).
70. Elter T, James R, Stilgenbauer S et al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL study group. ASH Annual Meeting Abstracts 114(22), 209 (2009).
71. Faderl S, Thomas DA, O'Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9), 3413-3415 (2003). (Pubitemid 36857922)
72. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10), 2360-2365 (2000).
73. Varghese AM, Cohen D, Pocock CFE et al. NCRN CLL207 study of alemtuzumab consolidation in CLL: final response assessment and early follow-up (on behalf of the NCRI CLL trials sub-group).ASH Annual Meeting Abstracts 116(21), 2360-2366 (2010).
74. Wierda WG, Kipps TJ, Durig J et al. Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia. Blood (2011) (In Press).
75. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase 3, randomised controlled trial. Lancet 377(9759), 42-51 (2011).
76. Del Poeta G, Del Principe MI, Buccisano F et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 112(1), 119-128 (2008).
77. O'Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98(12), 2657-2663 (2003). (Pubitemid 37509530)
78. Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).Leukemia 18(6), 1093-1101 (2004).
79. Schweighofer CD, Ritgen M, Eichhorst BF et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).Br. J. Haematol. 144(1), 95-98 (2009).
80. Lin TS, Donohue KA, Byrd JC et al. Consolidation therapy with subcutaneous (SC) alemtuzumab after fludarabine and rituximab (FR) induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB study 10101. J. Clin. Oncol. 28(29), 4500-4506 (2010).
81. Byrd JC, Peterson BL, Rai KR et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk. Lymphoma 50(10), 1589-1596 (2009).
82. Hainsworth JD, Vazquez ER, Spigel DR et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 112(6), 1288-1295 (2008). (Pubitemid 351429744)
83. Shanafelt T, Tun H, Hanson C et al. Lendalidomide consolidation after first-line chemoimmunotherapy for patients with previously untreated CLL. ASH Annual Meeting Abstracts 116(21), 1379 (2010).
84. Eichhorst BF, Busch R, Stauch M et al. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (C1b) in elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a phase III study of the German CLL study group (GCLLSG).Blood 110(11), 194a-194a (2007).
85. Hillmen P, Gribben JG, Follows GA et al. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label Phase II study. ASH Annual Meeting Abstracts 116(21), 697 (2010).
86. Foa R, Ciolli S, Di Raimondo F et al. A Phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis. ASH Annual Meeting Abstracts 116(21), 2462 (2010).
87. Castro JE, James DF, Sandoval-Sus JD et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 23(10), 1779-1789 (2009).
88. Dreger P, Dohner H, Ritgen M et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116(14), 2438-2447 (2010).
89. Stilgenbauer S, Cymbalista F, Leblond V et al. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p or refractory to fludarabine interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW. ASH Annual Meeting Abstracts 116(21), 920 (2010).
90. Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23(18), 4079-4088 (2005).
91. Tam CS, Wierda WG, O'Brien S et al. Life after fludarabine, cyclophosphamide, & rituximab (FCR) the clinical outcome of patients with chronic lymphocytic leukemia who receive salvage treatment after frontline FCR. ASH Annual Meeting Abstracts 112(11), 2090 (2008).
92. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (br) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre Phase II trial of the German CLL study group (GCLLSG).ASH Annual Meeting Abstracts 112(11), 330 (2008).